leadf
logo-loader
viewCytoDyn Inc.
(
OTCQB:CYDY
)

CytoDyn CEO talks through its two recent convertible debt financing efforts of $50M

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive it has completed an additional potentially non-dilutive convertible debt offering with an institutional investor, which provides $25 million of immediately available capital. Earlier this month, the company completed a similar convertible debt offering, also worth $25 million. Pourhassan talked through how the group will use the $50M, focusing on three key indications: COVID-19, HIV, and oncology.

Quick facts: CytoDyn Inc.

Follow
OTCQB:CYDY

Price: 2.32 USD

Market Cap: $1.47 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn says Brazil has approved a Phase 3 trial of its drug in critically...

CytoDyn Inc's Nader Pourhassan tells Proactive that Brazil’s regulatory authority Agência Nacional de Vigilância Sanitária (ANVISA) has approved the start of an additional Phase 3 CD16 clinical trial of its flagship drug leronlimab to treat critically ill coronavirus patients. Pourhassan says...

2 days, 7 hours ago

2 min read